Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937234 | 0.87 | SMN1; SMN2 (0.64) | KDM4ERAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL12154291 | 0.85 | KDM4E (0.66) | KDM4ERAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL12344791 | 0.85 | RAB9A (0.67) | KDM4ERAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL2169817 | 0.85 | RAB9A (0.62) | KDM4ERAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL2578444 | 0.85 | SMN1; SMN2 (0.59) | KDM4ERAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL9555373 | 0.85 | PTGDR2 (0.58) | KDM4ERAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL2073067 | 0.84 | RAB9A (0.61) | KDM4ERAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL9555535 | 0.84 | PTGDR2 (0.57) | KDM4ERAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL27839229 | 0.83 | RAB9A (0.59) | KDM4ERAB9ASMN1; SMN2NPC1POLB | |
| SCHEMBL9555341 | 0.82 | PTGDR2 (0.59) | KDM4ERAB9ASMN1; SMN2NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2089397-B1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8049013-B2 | 5- [4-(azetidin-3-yloxy)-phenyl]-2-phenyl-5H-thiazolo[5,4-C] pyridin-4-one derivatives and their use as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| CN-101558075-A | 5- [4- (azetidin-3-yl0xy) -phenyl] -2-phenyl-5h-thiaz0l0 [5,4-c] pyridin-4-0ne derivatives and their use as mch receptor antagonists | LILLY CO ELI (US) | 2009-10-14 | — | — | CN | disclosed |
| EP-2089397-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL]-2-PHENYL-5H-THIAZ0L0 [5,4-C]PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008076562-A1 | 5- [4- (AZETIDIN-3-YL0XY) -PHENYL] -2-PHENYL-5H-THIAZ0L0 [5,4-C] PYRIDIN-4-0NE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069352-A1 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, HCRTR1 | KDM4E 2614/4885RAB9A 3702/4885SMN1; SMN2 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.